Loading
A phase 1/2 trial of TCC1727 tablet（1） in advanced solid tumours, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. is a phase 1/2 interventional study registered as NCT05970016 by Beijing Tide Pharmaceutical Co., Ltd, with 56 participants planned, started 2023-08-07 and due to reach its primary completion in 2025-07-30. Interventions recorded: TCC1727 tablet（1） and TCC1727 tablet（2）.
Shares Beijing Tide Pharmaceutical and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.